George J. Hanna

Infectious Disease

1805 Stuart Rd W
Princeton, NJ 08540

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial.

Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial.

Journal: JAMA network open

Published: October 18, 2024

Topological functional network analysis of cortical blood flow in hyperacute ischemic rats.

Topological functional network analysis of cortical blood flow in hyperacute ischemic rats.

Journal: Brain structure & function

Published: June 07, 2024

Effect of Montelukast vs Placebo on Time to Sustained Recovery in Outpatients with COVID-19: The ACTIV-6 Randomized Clinical Trial.

Effect of Montelukast vs Placebo on Time to Sustained Recovery in Outpatients with COVID-19: The ACTIV-6 Randomized Clinical Trial.

Journal: medRxiv : the preprint server for health sciences

Published: May 27, 2024

Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.

Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.

Journal: JAMA

Published: November 17, 2023

Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19.

Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19.

Journal: The New England journal of medicine

Published: September 21, 2023

Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes.

Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes.

Journal: JAMA network open

Published: April 24, 2023

Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial.

Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial.

Journal: JAMA

Published: February 22, 2023

The Influence of Social Determinants on Receiving Outpatient Treatment with Monoclonal Antibodies, Disease Risk, and Effectiveness for COVID-19.

The Influence of Social Determinants on Receiving Outpatient Treatment with Monoclonal Antibodies, Disease Risk, and Effectiveness for COVID-19.

Journal: Journal of general internal medicine

Published: January 27, 2023

Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.

Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.

Journal: JAMA

Published: January 12, 2023

Effect of Ivermectin 600 μg/kg for 6 days vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial.

Effect of Ivermectin 600 μg/kg for 6 days vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial.

Journal: medRxiv : the preprint server for health sciences

Published: December 23, 2022

Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial.

Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial.

Journal: medRxiv : the preprint server for health sciences

Published: October 27, 2022

Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.

Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.

Journal: JAMA

Published: October 21, 2022

Showing 1-12 of 50

Last Updated: 09/26/2026